The Russia Viscosupplementation Market is poised for significant growth, with the single injection viscosupplementation segment set to experience the fastest expansion, growing at a CAGR of 6.0% during the forecast period. This growth is driven by relatively lower competition in the single injection segment compared to other product types.
On the other hand, the three injection viscosupplementation segment remains the most dominant and preferred treatment option for osteoarthritis in Russia. In 2016, this segment accounted for more than 69.4% of the market share and is expected to maintain a substantial share, reaching over 68.8% by the end of 2026. This trend underscores the strong preference for multiple injection therapies among patients and healthcare providers due to their proven efficacy in providing long-term relief.
By 2026, the three injection viscosupplementation segment is anticipated to surpass a market valuation of USD 23.5 million, reinforcing its position as the most attractive product type within the Russian viscosupplementation market.
Russia’s healthcare infrastructure will continue witnessing significant rise in number of orthopaedic patients as several bone & joint-related disorders are likely to be caused by people’s eating & drink habits, their proactive lifestyles and the country’s harsh weather conditions. Rising occurrence of joint-related ailments such as knee osteoarthritis in Russia are a result of people performing physical labour in severely cold weather conditions. This has necessitated the adoption of viscosupplementation as an ideal medical procedure for injecting lubricating fluid in bone joints during surgeries. An in-depth analysis of Russia Viscosupplementation Industry conducted by Future Market Insights, projects that demand for three-injection viscosupplementation will gain traction over the next decade.
The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026.
Top Players in Russia Viscosupplementation Industry
Top three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH and TRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues.
Key Market Insights:
- Single Injection Viscosupplementation: Expected to grow at the fastest pace, with a CAGR of 6.0%.
- Three Injection Viscosupplementation: Predicted to remain the dominant segment, holding a 69.4% market share in 2016 and expected to slightly decrease to 68.8% by 2026, while reaching a market value of over USD 23.5 million.
- Growth Drivers: Growing preference for multi-injection viscosupplementation in treating osteoarthritis and expanding adoption of viscosupplementation therapies across Russia.
As viscosupplementation continues to be a vital therapeutic approach for osteoarthritis management in Russia, the market is expected to see sustained growth driven by ongoing innovations and an increasing demand for effective joint pain treatments.
A Full Report Overview
The market is divided into two segments based on product type and end use
By Product Type
- Single Injection Viscosupplementation
- Three Injection Viscosupplementation
- Five Injection Viscosupplementation
By End Use
- Hospitals
- 500+ Bedded
- 250-500 Bedded
- Less Than 250 Bedded
- Ambulatory Surgical Centres
- Orthopaedic Clinics
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube